3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
Paclitaxel
28
Carboplatin
28
pembrolizumab
25
Bevacizumab
14
liposomal doxorubicin
12
Cisplatin
11
Gemcitabine
10
Radiotherapy
8
Drug Therapy
8
Cyclophosphamide
8
Blood Specimen Collection
8
Topotecan
7
Nivolumab
7
olaparib
6
Doxorubicin
6
niraparib
5
Therapeutics
5
Dexamethasone
5
pertuzumab
4
pazopanib
4
lenvatinib
4
fludarabine
4
cemiplimab
4
atezolizumab
4
Trastuzumab
4
Surveys and Questionnaires
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled